Introduction: Intracerebral hemorrhage (ICH) is a lethal and highly morbid stroke subtype lacking disease-specific treatment (1). Inflammation after ICH is an important mechanism of secondary damage, and the inflamed endothelium in ICH is a promising therapeutic target as it is the gateway for inflammation into the brain (2). We hypothesized that targeting mRNA encoding IL-10, a potent anti-inflammatory therapy, to the brain endothelium via vascular cellular adhesion molecule (VCAM)-targeted lipid nanoparticles (LNPs) would lead to improved outcomes in an experimental mouse model of ICH.
Learning Objectives:
Describe the therapeutic effect of targeted IL-10 mRNA delivery in experimental ICH.
Understand the novel insights into ICH pathophysiology uncovered in this study.
Generalize the use of VCAM-LNPs as a platform technology to treat other neurological diseases.
